• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New treatments for colorectal cancer.

出版信息

FDA Consum. 2004 May-Jun;38(3):17.

PMID:15218840
Abstract
摘要

相似文献

1
New treatments for colorectal cancer.
FDA Consum. 2004 May-Jun;38(3):17.
2
[Progress of chemotherapy in colorectal cancer].
Gan To Kagaku Ryoho. 2007 Nov;34(11):1771-6.
3
Bevacizumab in colorectal cancer.贝伐单抗用于结直肠癌治疗
N Engl J Med. 2004 Oct 14;351(16):1690-1; author reply 1690-1.
4
[Improving longevity in advanced intestinal cancer].[提高晚期肠癌的生存期]
Krankenpfl J. 2005;43(1-3):48.
5
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.在一组非选择性转移性结直肠癌患者中，短期输注贝伐单抗联合基于5-氟尿嘧啶的化疗作为一线治疗方案。
Acta Oncol. 2010 Apr;49(3):395-6. doi: 10.3109/02841860903428184.
6
Perforating dermatosis in a patient receiving bevacizumab.一名接受贝伐单抗治疗的患者出现了穿通性皮肤病。
J Eur Acad Dermatol Venereol. 2009 Aug;23(8):972-4. doi: 10.1111/j.1468-3083.2008.03078.x. Epub 2009 Mar 17.
7
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.贝伐单抗治疗结直肠癌患者期间的晚期吻合口裂开
Clin Oncol (R Coll Radiol). 2011 Sep;23(7):497-8. doi: 10.1016/j.clon.2011.03.009. Epub 2011 May 14.
8
ERBITUX as a single agent and in combination in colorectal carcinoma.
Expert Rev Anticancer Ther. 2002 Jun;2(3):242.
9
Bevacizumab for advanced colorectal cancer.
Issues Emerg Health Technol. 2004 Dec(63):1-4.
10
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.关于“贝伐单抗治疗与未治疗的结直肠癌：一项III期研究”的评论
Oncology. 2011;80(1-2):138-9. doi: 10.1159/000327237. Epub 2011 Jun 15.

引用本文的文献

1
Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial.围手术期化疗联合贝伐单抗治疗潜在可治愈的转移性结直肠癌：ASSO-LM1试验的长期随访
Cancers (Basel). 2024 Feb 21;16(5):857. doi: 10.3390/cancers16050857.
2
Current Targeted Therapy for Metastatic Colorectal Cancer.转移性结直肠癌的当前靶向治疗。
Int J Mol Sci. 2023 Jan 15;24(2):1702. doi: 10.3390/ijms24021702.
3
Evolution of intravitreal therapy for retinal and macular disorders.视网膜和黄斑疾病玻璃体内治疗的进展
J Int Med Res. 2020 Jan;48(1):300060518771411. doi: 10.1177/0300060518771411. Epub 2018 May 4.
4
The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.血管生成抑制疗法联合放射疗法的临床应用：过去、现在与未来
Angiogenesis. 2017 May;20(2):217-232. doi: 10.1007/s10456-017-9546-9. Epub 2017 Mar 31.
5
Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach.抗血管内皮生长因子药物治疗与新生血管性年龄相关性黄斑变性相关的色素上皮脱离：循证医学方法
Med Hypothesis Discov Innov Ophthalmol. 2015 Winter;4(4):127-129.
6
Targeting receptor tyrosine kinases in gastric cancer.靶向胃癌中的受体酪氨酸激酶
World J Gastroenterol. 2014 Apr 28;20(16):4536-45. doi: 10.3748/wjg.v20.i16.4536.
7
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.针对 CD105 的新型李斯特菌基疫苗靶向肿瘤血管生成。
Cancer Immunol Immunother. 2011 Jul;60(7):931-42. doi: 10.1007/s00262-011-1002-x. Epub 2011 Mar 23.
8
Data-driven methods to discover molecular determinants of serious adverse drug events.用于发现严重药物不良事件分子决定因素的数据驱动方法。
Clin Pharmacol Ther. 2009 Mar;85(3):259-68. doi: 10.1038/clpt.2008.274. Epub 2009 Jan 28.